Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-Fine: Dabigatran Etexilate in Elective PCI
2007-007536-25Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dabigatran in acute coronary syndrome (ACS) and coronary arteriosclerosis (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Anticoagulant effect during PCI. Started Jun 2008; status: completed.
02
Drugs
dabigatran
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on 2007-007536-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007536-25.